QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$23.39
-0.3%
$31.21
$22.42
$59.61
$1.13B1.38684,745 shs976,148 shs
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$80.37
$82.48
$39.40
$89.76
$3.58B1.55626,604 shsN/A
Haemonetics Co. stock logo
HAE
Haemonetics
$83.46
-1.7%
$78.72
$70.74
$95.26
$4.24B0.36449,436 shs966,334 shs
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$70.99
-0.7%
$75.41
$62.58
$85.62
$4.12B0.89500,244 shs269,998 shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+1.52%-9.46%-26.58%-28.94%-43.72%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00%0.00%0.00%0.00%0.00%
Haemonetics Co. stock logo
HAE
Haemonetics
+0.80%-1.50%+11.98%+1.65%-0.14%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
-1.70%-0.61%-0.96%-8.92%-5.98%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-7.10%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
1.6492 of 5 stars
3.51.00.00.01.92.50.6
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
4.4757 of 5 stars
3.34.00.04.32.31.71.9
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
4.9442 of 5 stars
4.44.00.03.82.82.52.5
NuVasive, Inc. stock logo
NUVA
NuVasive
1.8793 of 5 stars
3.30.00.00.00.00.03.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$55.57137.59% Upside
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6725.41% Upside
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
2.89
Moderate Buy$92.5030.30% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside

Current Analyst Ratings

Latest ATRC, NUVA, MMSI, CMD, and HAE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$98.00
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$88.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$88.00
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$82.00 ➝ $87.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $88.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $98.00
2/29/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$102.00 ➝ $112.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $58.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $42.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$399.24M2.83N/AN/A$9.84 per share2.38
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$1.02B3.52$3.38 per share23.78$17.31 per share4.64
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.63$4.93 per share16.92$16.22 per share5.15
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$1.26B3.28$4.71 per share15.07$20.81 per share3.41
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.66N/AN/AN/A-7.62%-7.55%-5.83%5/1/2024 (Confirmed)
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4633.9319.781.999.97%22.37%9.71%5/9/2024 (Confirmed)
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$94.41M$1.6243.8219.402.037.51%14.63%9.19%4/30/2024 (Confirmed)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A

Latest ATRC, NUVA, MMSI, CMD, and HAE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/1/2024N/A
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.20N/A+$0.20N/AN/AN/A  
4/30/2024N/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.70N/A-$0.70N/AN/AN/A  
2/28/2024Q4 2023
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.77$0.81+$0.04$1.15$320.66 million$324.52 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$0.210.26%N/A12.73%N/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.15
3.57
2.66
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.16
2.72
2.00
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
0.68
5.45
3.95
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
84.13%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
99.66%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
10.70%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
3.70%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20048.38 million46.83 millionOptionable
Cantel Medical Corp. stock logo
CMD
Cantel Medical
3,66944.51 millionN/AOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
6,95058.06 million55.92 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable

ATRC, NUVA, MMSI, CMD, and HAE Headlines

SourceHeadline
Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032
pharmiweb.com - April 18 at 10:34 AM
SMAIO Publishes its 2023 Annual ResultsSMAIO Publishes its 2023 Annual Results
finance.yahoo.com - April 17 at 6:36 PM
This Week in Chancery Court: Poison Pill Ruling, NuVasiveThis Week in Chancery Court: Poison Pill Ruling, NuVasive
news.bloomberglaw.com - April 15 at 8:58 AM
Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032
taiwannews.com.tw - April 12 at 7:59 AM
10 robots used in spine surgery10 robots used in spine surgery
beckersspine.com - April 10 at 6:27 PM
Global Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market PlayersGlobal Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market Players
finance.yahoo.com - April 9 at 10:20 AM
Accelus adds 2 leadersAccelus adds 2 leaders
beckersspine.com - April 3 at 3:20 PM
$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028
finance.yahoo.com - April 3 at 10:19 AM
Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%
fmiblog.com - April 2 at 2:16 PM
Globus Medical director sells $550K in stockGlobus Medical director sells $550K in stock
beckersspine.com - March 20 at 4:48 PM
Orthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGROrthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGR
pharmiweb.com - March 14 at 9:11 AM
Wrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.usWrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.us
pharmiweb.com - March 13 at 10:23 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™
prnewswire.co.uk - March 13 at 10:23 PM
UK reinstates modified MAGEC X system for scoliosis treatmentsUK reinstates modified MAGEC X system for scoliosis treatments
msn.com - March 13 at 5:22 PM
Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033
pharmiweb.com - March 12 at 4:16 PM
Orthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust GrowthOrthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust Growth
finance.yahoo.com - March 12 at 4:16 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarketsMinimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets
finanznachrichten.de - March 12 at 9:26 AM
NuVasive and Zimmer Biomet welcomed by MedAccred programNuVasive and Zimmer Biomet welcomed by MedAccred program
medicalplasticsnews.com - March 6 at 4:00 PM
J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of DirectorsJ. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors
finance.yahoo.com - March 5 at 2:31 PM
Crushed Great Ormond Street hospital patients left in limbo after treatment axedCrushed Great Ormond Street hospital patients 'left in limbo' after treatment axed
express.co.uk - February 22 at 9:18 AM
Great Ormond Street patient cant get MAGEC spine operationGreat Ormond Street patient can't get MAGEC spine operation
newsshopper.co.uk - February 22 at 12:47 AM
Q4 2023 Globus Medical Inc Earnings CallQ4 2023 Globus Medical Inc Earnings Call
uk.finance.yahoo.com - February 21 at 2:46 PM
Globus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration RisksGlobus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration Risks
markets.businessinsider.com - February 21 at 2:46 PM
Layoffs beget layoffs: Why 2024 could be the year of cut costs'Layoffs beget layoffs': Why 2024 could be the year of cut costs
beckersasc.com - February 19 at 8:11 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Cantel Medical logo

Cantel Medical

NYSE:CMD
Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Merit Medical Systems logo

Merit Medical Systems

NASDAQ:MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.